A single dose of BNT162b2 vaccine elicits strong humoral response in SARS-CoV-2 seropositive individuals

Allergy. 2022 Jan;77(1):296-298. doi: 10.1111/all.15047. Epub 2021 Aug 21.

Authors

Teodora Brnjarchevska Blazhevska¹, Haris Babačić², Olgica Sibinovska¹, Boban Dobrevski¹, Meri Kirijas¹, Gorjan Milanovski¹, Todor Arsov^{1

3}, Aleksandar Petlichkovski¹

Affiliations

¹ Faculty of Medicine-Skopje, Institute for Immunobiology and Human Genetics, Ss. Cyril and Methodius University, Skopje, North Macedonia.
² Karolinska Institute, Stockholm, Sweden.
³ John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19*
Humans
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Vaccines*

Substances

Spike Glycoprotein, Coronavirus
Vaccines
BNT162 Vaccine

Grants and funding